Zenas BioPharma (ZBIO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.0M

Revenue (quarter)

$1.0M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$1.0M

Gross margin

100.00%

Net income (trailing twelve months)

−$484.4M

Net income (quarter)

−$111.5M

Net income growth (year over year)

−113.42%

Net margin

−48438.40%

Return on equity

−199.04%

EPS (trailing twelve months)

−$9.63

Book value per share

$3.90

P/E (trailing twelve months)

—

Price to book

6.64

Debt to assets

64.79%

Payout ratio

—

Dividend yield

—

Company profile

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

• Is Zenas BioPharma (ZBIO) profitable?

  No. Zenas BioPharma reported a net loss of $484.4M over the trailing twelve months.

• How much revenue does Zenas BioPharma (ZBIO) make?

  Zenas BioPharma generated $1.0M in revenue over the trailing twelve months.

• How do I buy stock in Zenas BioPharma (ZBIO)?

  ZBIO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.